What ChrysCapital is

Established in 1999, ChrysCapital is one of India's largest and longest-running homegrown private equity firms. Built on 25+ years of industry expertise and one of the most stable teams in Indian private equity, it has delivered what it describes as industry-leading realisations to a global investor base.

Investment thesis

ChrysCapital's stated philosophy is simple: find best-in-class companies in high-growth, high-ROCE (return on capital employed) sectors that are open to working with investors as agents of change, and drive consistent performance across economic cycles. Its four principles: deep sector knowledge (20+ years in core sectors), disciplined investing (rigorous risk-reward assessment), a long-term perspective (“today's fallen stars can become tomorrow's angels”), and a sharp focus on exits — a clear exit plan at the time of investment, cash-on-cash returns, and “protecting the portfolio” by taking chips off the table at regular intervals. Operational value-add runs through Enhancin, its in-house portfolio value-creation team. The firm does both minority growth and control deals, including buyouts and carve-outs.

Sectors and stages

ChrysCapital invests in growth-stage and buyout transactions across six focus sectors: consumer, enterprise technology, financial services, healthcare & life sciences, manufacturing, and new economy.

Fund size and cheque sizes

In November 2025 ChrysCapital closed ChrysCapital X at $2.2 billion — the largest private equity fund ever raised by a domestic Indian PE firm, and a more than 60% jump over the $1.35 billion Fund IX (2022). Since inception the firm has cumulatively raised close to $8.5 billion across ten PE funds, a continuation vehicle and its public markets fund; it has deployed over $5.5 billion in more than 110 portfolio companies and returned almost $7.8 billion at a 3.0x ROI from 80+ exits. The firm publishes no formal cheque-size range; its dealbook spans growth-equity minority stakes to control buyouts, such as a roughly 90% stake in Theobroma Foods for ₹2,410 crore in 2025.

Notable portfolio and exits

ChrysCapital's pharma and healthcare franchise is legendary: Intas Pharmaceuticals, Mankind Pharma (exited at a 24% IRR — ₹2,210 crore in, ₹7,510 crore out), Eris Lifesciences, Curatio Healthcare, Torrent Pharmaceuticals, La Renon, Centre for Sight and GeBBS Healthcare (sold to EQT in 2024). In financial services: the National Stock Exchange, AU Small Finance Bank, Shriram Finance, Bandhan AMC (the IDFC AMC buyout, with Bandhan Bank and GIC) and Credila (bought with EQT). In technology: Infosys, HCL Technologies, Mphasis, Infogain, Cyient and Xoriant (control buyout). New-economy and consumer names include Lenskart, Dream11, FirstCry, Awfis, HealthKart and The Sleep Company.

Partners and team

Kunal Shroff is Managing Partner (quoted by ET on the Fund X close); Managing Directors on the firm's website include Rajiv Batra, recognised in ET's 40 Under Forty 2026.

Programmes, accelerators and perks

ChrysCapital runs no public accelerator, incubator or structured founder programme — it is a growth-equity and buyout house, not an early-stage platform. It has no publicly documented startup credits or perks programme.

Why it matters for founders

ChrysCapital matters when your company is past the startup phase: it is the partner of choice for profitable, scaling businesses — especially in pharma, financial services and IT services — that want a growth-equity or buyout investor with a 25-year record of building companies and exiting them at strong multiples. With $2.2 billion of fresh Fund X firepower to deploy over the next three to four years, established founders have a rare window to engage India's most storied homegrown PE franchise.